Insider buying last 90 days
No open-market insider purchases were filed for BCAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BCAX insider filing, plotted on the chart in Gekko.Open BCAX in Gekko
NASDAQ: BCAX
Bicara Therapeutics (BCAX) Stock Analysis & Forecast
Oct 12 close
$17.33−0.17 (−1.0%)
Gekko Brief
AI summaryOct 12 closeThis week brings continued attention to BMO Capital's maintained Buy rating on Bicara Therapeutics, with the firm reiterating its $35 price target. Inducement grants were also announced for two new employees on 1 October 2026 under Nasdaq Listing Rule 5635(c)(4), covering non-qualified stock options at an $18.20 exercise price. T. Rowe Price filed an ownership amendment reporting beneficial ownership of 2.8 million shares, representing 4.2% of the class, as of 30 September 2026.
BCAX closed at $17.33, down 1% on the day, with the close sitting between its 50-day average of $22.48 and 200-day average of $21.29. The stock has fallen 24% over one month and 38.3% over three months, though it remains down just 5.1% over one year. The GekkoIndex reads 69.2, placing the stock in the Accumulation zone, down 4 points over five days. Price sits 31.6% below Gekko Fair Value of $25.33.
Bicara's next earnings report is scheduled for 9 November 2026 before the open, 28 days away and within a typical 20-trading-day holding window. The prior report on 11 August showed an EPS miss, with actual results of -$0.82 against an estimate of -$0.77, triggering an 11.2% reaction; the company has beaten estimates in 2 of its last 7 quarters. Analyst consensus across 10 firms stands at 7 buy and 3 hold ratings, with a consensus target of $35.50. No insider, Congress, or unusual options activity appears in current windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Bicara Therapeutics price vs fair value
Close $17.33200-day averageGekko Fair Value $25.33
Bicara Therapeutics quick facts
- Market cap
- $1.14B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.05
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -0.69
- Volume
- 659,114 avg 787,298
- 1-year return
- −5.1%
- Typical daily move
- ±7%
- Typical 20-day move
- ±13.3%
- 50-day average
- $22.48
- 200-day average
- $21.29
- Next earnings
- Nov 9 before open
- Shares outstanding
- 66.17M
Bicara Therapeutics swing-trade checklist
Bicara Therapeutics scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $17.33 sits between the 50-day ($22.48) and 200-day ($21.29) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.2, Accumulation
Reading 69.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
31.6% below
Price is 31.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Bicara Therapeutics stock chart and price history
Bicara Therapeutics closed at $17.33 on Oct 12, 2026, −5.1% over the past year, inside a 52-week range of $13.70 to $30.99.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −24.0%
- 3 months
- −38.3%
- 6 months
- −21.7%
- 1 year
- −5.1%
The full BCAX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BCAX in Gekko
Follow Bicara Therapeutics through every session
Put BCAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BCAX in GekkoFree for 7 days. No credit card required.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody designed to act on cancer cells in two ways at once, targeting the epidermal growth factor receptor while also binding to human transforming growth factor beta. This dual-action approach to solid tumor treatment is the company's primary area of work.
The company functions as a subsidiary of Biocon Limited, operating within that broader corporate structure as it advances its pipeline through clinical development.
Bicara Therapeutics is based in Boston, Massachusetts, and was founded in 2018. Its shares are listed on the NASDAQ under the ticker BCAX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- bicara.com
Bicara Therapeutics GekkoIndex: the smart money zone
Bicara Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.2, in the Accumulation zone, down 4 points over five sessions.
69.2Accumulation
Down 4 points over five sessions, from the Buying zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | +1.7% | +7.3% | ||
| Accumulation (current zone) | 199 | +2.7% | +5.8% | ||
| Neutral | 248 | −2.2% | −2.1% | ||
| Distribution | 35 | +2.4% | −4.4% | ||
| Selling | 4 | Too few readings yet | |||
Average BCAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BCAX price, zone by zone.Track BCAX in Gekko
Is Bicara Therapeutics stock overvalued? Gekko Fair Value
Bicara Therapeutics trades 31.6% below Gekko Fair Value of $25.33, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Bicara Therapeutics shares are worth, recalculated every trading day.
$25.33
Gekko Fair Value, Oct 9, 2026
31.6% Undervalued
At the end of Aug 2026 the price was 25.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BCAX in Gekko
Bicara Therapeutics insider and Congress trading
No open-market insider purchases were filed for Bicara Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BCAX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BCAX, plotted on the chart in Gekko.Open BCAX in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold BCAX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bicara Therapeutics earnings: next date and track record
Bicara Therapeutics reports on Nov 9, 2026, before the open (28 days away), and beat the EPS estimate in 2 of its last 7 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 28 days away
- EPS estimate
- −$0.84
2 of 7reports beat the EPS estimate
±5.9%average move across the report
3 of 7reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Bicara Therapeutics reported Q2 2026 results focused on advancing the pivotal Phase III FORTIFI-HN01 study of ficerafusp alfa in frontline recurrent/metastatic HPV-negative head and neck squamous cell cancer. ASCO 2026 data showed 3-year follow-up with Ficera nearly doubling overall survival versus standard of care. The company announced CEO transition with Ryan Cohlhepp replacing Claire Mazumdar, and a new CFO Jenn Larson replacing Ivan Hyep, who oversaw $800M+ in capital raises.
- Guidance
- Management anticipates a top-line interim analysis of the pivotal FORTIFI-HN01 study that could lead to accelerated approval and subsequent commercial launch. Leadership transitions are explicitly tied to preparing for potential commercialization of Ficera.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.82 est −$0.77 | — | −11.2% |
| Mar 26, 2026 | −$0.68 est −$0.72 | — | −1.7% |
| Nov 10, 2025 | −$0.67 est −$0.53 | — | +0.6% |
| Aug 12, 2025 | −$0.50 est −$0.54 | — | +13.4% |
| May 13, 2025 | −$0.68 est −$0.40 | — | −3.5% |
| Mar 27, 2025 | −$0.39 est −$0.28 | — | +2.3% |
| Nov 12, 2024 | −$1.60 est −$0.46 | — | −8.8% |
| Dec 31, 2023 | −$0.23 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bicara Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Bicara Therapeutics is $35.50, +104.8% from the last close, from 10 firms rating the stock in the last 90 days.
$35.50consensus 12-month target, +104.8% from the last close
Now $17.33Avg $35.50
Low $20High $45
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | BMO Capital | $35 | +102.0% |
| Sep 8 | JonesTrading | $30 | +73.1% |
| Aug 18 | BMO Capital | $35 | +102.0% |
| Aug 13 | Stifel Nicolaus | $45 | +159.7% |
| Aug 13 | Mizuho Securities | $20 | +15.4% |
+5.8%average 20-day move after past Accumulation readings
±7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bicara Therapeutics market cap and key statistics
Bicara Therapeutics’s market cap is $1.14B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.14B
- EPS, TTM
- −$3.05
- Gekko Fair Value
- $25.33
Trading
- Volume
- 659,114
- Avg volume, 20 days
- 787,298
- 52-week high
- $30.99
- 52-week low
- $13.70
- Shares outstanding
- 66.17M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -41%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.69
- Typical daily move
- ±7%
- Typical 20-day move
- ±13.3%
Bicara Therapeutics stock news this week
Coverage of Bicara Therapeutics this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- T. Rowe Price lists 2.8 million shares in Bicara Therapeutics (BCAX) ownership amendment.Stock Titan, Oct 8
- BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35Moomoo, Oct 8
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire, Oct 6
Bicara Therapeutics peers
Bicara Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Bicara Therapeutics stock FAQ
What is Bicara Therapeutics’s market cap?
Bicara Therapeutics’s market cap is $1.14B at the Oct 12, 2026 close of $17.33, with 66.17M shares outstanding.
What is the Bicara Therapeutics stock forecast?
The consensus analyst 12-month price target for Bicara Therapeutics is $35.50, +104.8% from the last close. Of the 10 firms that rated the stock in the last 90 days, 7 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Bicara Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Bicara Therapeutics is undervalued: the Oct 12, 2026 close of $17.33 is 31.6% below Gekko Fair Value of $25.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bicara Therapeutics report earnings next?
Bicara Therapeutics is expected to report on Nov 9, 2026, before the market opens (28 days away). Analysts expect earnings of −$0.84 per share. Bicara Therapeutics beat the earnings estimate in 2 of its last 7 reports, moving 5.9% on average across the report.
What is Bicara Therapeutics’s 52-week high and low?
Bicara Therapeutics’s 52-week high is $30.99 and its 52-week low is $13.70; it closed at $17.33 on Oct 12, 2026, −5.1% over the past year.
Is Bicara Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bicara Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.